Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Small extracellular vesicles from adipose derived stem cells alleviate microglia activation and improve motor deficit of Parkinson's disease via miR-100-5p/DTX3L/STAT1 signaling axis.

Feng N., Huang X., Jia Y.

Animal Study on Neuroinflammation, Chronic Inflammation, published in Exp Neurol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Exp Neurol (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40194649
DOI
10.1016/j.expneurol.2025.115250
Citations
3

Abstract (original English)

Dopaminergic neuron loss caused by microglia activation is an important pathological factor of Parkinson's disease (PD). Previously, we reported that small extracellular vesicle from adipose derived stem cells (ADSC-sEVs) could inhibit the activation of microglia and protect neuron apoptosis from microglia activation. However, whether ADSC-sEVs have protective effect on the motor deficit of PD mouse and the exact mechanism remains unknown. In this study, ADSC-sEVs were delivered to experimental model of Parkinson's disease by tail vein injection to explore the in vivo effect of ADSC-sEVs on PD. Next, the potential key microRNA in ADSC-sEVs was screened by RNA sequencing (RNA-seq), and the exact mechanism was further explored. We found that ADSC-sEVs greatly alleviated the activation of microglia and reduced the loss of dopaminergic neurons in the substantia nigra of PD mice, the motor deficit was also significantly improved. By RNA-seq analysis, miR-100-5p was verified as a potential microRNA in this process, because knockdown of miR-100-5p in ADSC-sEVs weakened the protective effect of ADSC-sEVs on PD mouse as well as the anti-inflammatory effect on microglia activation. Finally, we found that miR-100-5p could target Deltex E3 ubiquitin ligase 3 L (DTX3L) and suppress its expression, which then decreased the expression and phosphorylation of Signal Transducers and Activators o

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMicrogliaMicroRNAsExtracellular VesiclesMiceSignal TransductionMice, Inbred C57BLSTAT1 Transcription FactorMaleAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research